Atreca to Present at Two Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present at two upcoming investor conferences:
- Stifel Healthcare Conference 2019
Date: Tuesday, November 19, 2019
Presentation Time: 10:55 a.m. EST
Location: New York, NY - Evercore ISI HealthCONx Conference
Date: Tuesday, December 3, 2019
Presentation Time: 10:15 a.m. EST
Location: Boston, MA
Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at . Archived replays of the webcasts will be available on the company's website for 90 days following each live presentation.
About Atreca, Inc.
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca’s discovery platform relies on the human immune system to discover unique antibody-target pairs from patients experiencing an active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets and provide the basis for novel clinical therapeutic candidates such as ATRC-101, the company’s lead clinical candidate. The company expects to file an Investigational New Drug application for ATRC-101 by the end of 2019 and to commence a Phase 1b study in multiple solid tumor types in early 2020. For more information on Atreca, please visit .
Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
Investors:
Alex Gray, 650-779-9251, ext. 251
Source: Atreca, Inc.
